Oestrogen Treatment for COVID-19 Symptoms

• Status: Not yet recruiting
• Trial end date: 2022-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this trial is to determine whether oestrogen treatment mitigates disease progression and severity in confirmed COVID19.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamad Medical Corporation
• Collaborator: Laboratoires Besins International
• Treatments: Estradiol

Criteria

Inclusion Criteria:

• Acute Covid-19 disease (PCR-confirmed or clinically diagnosed with high certainty)

• Adult males > 18 years of age OR

• Post-menopausal women (spontaneous amenorrhoea for >12 months in the absence of any other cause)

Exclusion Criteria:

Women:

• taking oestrogen supplements or oestrogen receptor antagonists

• with abnormal genital bleeding

• with a history of breast cancer

• with a history of endometrial or ovarian cancer

• with untreated endometrial hyperplasia

Men:

• taking hormone therapies (e.g. for prostate cancer)

Any subject:

• failure to obtain consent

• taking lamotrigine

• with a thromboembolic disorder (e.g. Protein C or Protein S deficiency, antithrombin III deficiency)

• with pre-existing liver or renal disease

• with known allergy to exogenous oestrogens

• with a history of porphyria

• with a history of thromboembolic event including deep vein thrombosis, thromboembolic stroke or pulmonary emboli

• taking part in another interventional clinical trial